Literature DB >> 33936367

Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review.

Peipei Xu1, Hong Chu1, Xiaoyan Shao1, Ying Jiang1, Chaoyang Guan1, Ming Chen2, Bing Chen1.   

Abstract

Multiple myeloma (MM) is a type of malignant disease that is characterized by a clonal proliferation of plasma cells within the bone marrow. Relapsed and refractory multiple myeloma (RRMM) is a subtype of MM that is unreactive to salvage therapy and progresses during treatment or within 60 days of the last therapy in patients who achieved a minimal response before progression of disease. This usually results in a poor prognosis. Extramedullary plasmacytoma (EMP) occurs when MM occasionally develops in tissues other than bones marrow. To the best of our knowledge, case studies of the presence of EMPs in the spleen have rarely been reported. Teratoma is a type of congenital tumor that consists of tissue that arises from pluripotent embryonic cells. Here we report a case of refractory immunoglobulin G (IgG) MM with both splenic plasmacytomas and a suspicious teratoma. To investigate the clinical and treatment features of patients under similar conditions, we also reviewed the available literature supporting the useful information in the pathogenesis, diagnosis and treatment of RRMM with EMP. IJCEP
Copyright © 2021.

Entities:  

Keywords:  Multiple myeloma; primary extramedullary plasmacytomas; teratoma

Year:  2021        PMID: 33936367      PMCID: PMC8085831     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  40 in total

1.  The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Authors:  Paul G Richardson; Jacob P Laubach; Robert L Schlossman; Irene M Ghobrial; Katherine C Redman; Mary McKenney; Diane Warren; Kimberly Noonan; Laura Lunde; Deborah Doss; Kathleen Colson; Teru Hideshima; Constantine Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Journal:  Eur J Haematol       Date:  2012-03-07       Impact factor: 2.997

2.  Non-secretory solitary plasmacytoma of the spleen.

Authors:  M D Colović; G M Janković; R B Colović; V M Martinović-Cemerikić
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

3.  Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.

Authors:  Joshua Richter; Noa Biran; Narjust Duma; David H Vesole; David Siegel
Journal:  Hematol Oncol       Date:  2016-03-27       Impact factor: 5.271

4.  Multiple myeloma with intracranial extension and bilateral renal infiltration: A case report and review of the literature.

Authors:  Min-Juan Zhang; Guo-Hong Su; Jie Shen; Feng-Hai Liu; Yan-Feng Xu; Xiao-Ling Zhang; Qing Wang; Rui-Huan Wang; Chun-Yan Liu; Yu-Lei Zhao
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

Review 5.  Teratoma: from spontaneous tumors to the pluripotency/malignancy assay.

Authors:  Floriana Bulic-Jakus; Ana Katusic Bojanac; Gordana Juric-Lekic; Maja Vlahovic; Nino Sincic
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-12-23       Impact factor: 5.814

Review 6.  Current treatment landscape for relapsed and/or refractory multiple myeloma.

Authors:  Meletios A Dimopoulos; Paul G Richardson; Philippe Moreau; Kenneth C Anderson
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

Review 7.  Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.

Authors:  Emily Ashjian; Kimberly Redic
Journal:  J Oncol Pharm Pract       Date:  2015-02-17       Impact factor: 1.809

8.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.

Authors:  Marcus Kremer; German Ott; Michaela Nathrath; Katja Specht; Katrin Stecker; Christoph Alexiou; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

9.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.

Authors:  Neil Sheth; Joanna Yeung; Hong Chang
Journal:  Leuk Res       Date:  2009-02-08       Impact factor: 3.156

10.  Computed tomography findings of a solitary extramedullary plasmacytoma of the spleen: A case report and literature review.

Authors:  Ying Wang; Li Yang; Zi-Hua Qian; Xiu-Liang Zhu; Ri-Sheng Yu
Journal:  Oncol Lett       Date:  2014-11-07       Impact factor: 2.967

View more
  1 in total

1.  A Rare Case of Extra-Medullary Portacaval Plasmacytoma in a Patient With Relapsed Multiple Myeloma.

Authors:  Nyan A Bethel; Folasade Ajayi; Henna Asrar; Sahithi Chittamuri; Hamid Shaaban
Journal:  Cureus       Date:  2022-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.